← Eichor
Study identifier: NCT06415669 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Condition: Gastric/Gastroesophageal Junction Adenocarcinoma  ·  Sponsor: The First Affiliated Hospital of Xiamen University

PhasePhase 2
Planned participants30
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

To evaluate the initial efficacy and safety of paclitaxel for injection (albumin-bound) in combination with apatinib mesylate and adebrelimab in the treatment of locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma following the progression of previous immunotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Mingquan Cai  ·  13696908231  ·  mingquan035@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

The First Affiliated Hospital of Xiamen UniversityFuzhou, Fujian, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06415669